¿ Aphton Corp., of Houston, said it has initiated late-stage human trials in the U.S. to treat metastatic gastric (stomach) cancer with its proprietary anti-G17 immunogen. Clinical investigators will use a combination immuno-chemo therapy regimen of Aphton's anti-G17 immunogen and 5-FU plus cisplatin. Aphton believes that its anti-G17 immunogen therapy can extend life without adding toxicity to the regimen.

¿ Biolog Inc., of Hayward, Calif., was awarded a Phase II grant from the National Institutes of Health for further development of the company's proprietary Phenotype MicroArray technology. The new grant provides $750,000 over two years.

¿ Coulter Pharmaceutical Inc., of South San Francisco, and SmithKline Beecham plc, of Philadelphia, said they initiated a Phase II multicenter investigational trial of Bexxar in combination with CVP (cyclophosphamide, vincristine and prednisone), a chemotherapy regimen to treat previously untreated low-grade non-Hodgkin's lymphoma (NHL). The companies initiated the trial to further investigate the first-line clinical use of Bexxar. The Phase II open-label trail will include 30 previously untreated low-grade NHL patients who will receive six cycles of CVP followed within 56 days of Bexxar.

¿ CV Therapeutics Inc., of Palo Alto, Calif., said it selected CVT-3146, a short-acting selective A2A adenosine receptor agonist, as its next clinical candidate. CVT-3146 is being developed for potential use as an adjunctive pharmacologic agent in cardiac perfusion imaging studies.

¿ Digene Corp., of Beltsville, Md., entered into an exclusive worldwide license with the Institut Pasteur, of Paris, to U.S. Patent No. 5,981,173, Genital Human Papillomavirus Type 68A (HPV 68A), related to the potentially oncogenic HPV 39. The license is exclusive for the field of HPV in vitro human diagnostics and HPV in vitro preclinical and clinical diagnostic testing for HPV vaccine and therapeutic discovery and development.

¿ GenVec Inc., of Gaithersburg, Md., said a randomized Phase II study has begun with BioBypass angiogenic agent, a new product designed to treat coronary artery disease and peripheral vascular disease. The new gene-based therapy is GenVec's lead product candidate and is designed to stimulate new blood vessel formation in the heart and other tissues affected by inadequate blood flow. The initial trial will include about 70 patients with severe coronary artery disease who are not candidates for bypass surgery.

¿ Immtech International Inc., of Vernon Hills, Ill., said DB-075, a new drug that is entering clinical trials later this year to treat diarrhea caused by Cryptosporidum parvum, also was found to be active against Giardia Lambia, the two most common parasites found in drinking water that cause severe diarrhea. Immtech intends to seek fast-track FDA approvals for DB-075.

¿ Ivax Corp., of Miami, received marketing approval in Canada for Paxene, its anticancer drug for the treatment of AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy.

¿ Maxim Pharmaceuticals, of San Diego, said its common stock will begin trading today, April 27, on the Nasdaq National Market under the symbol MAXM. The company's redeemable common stock purchase warrants also will commence trading on the Nasdaq National Market under the symbol MAXMW. As a result, trading of the company's common stock and warrant securities on the American Stock Exchange were to be suspended after the close of trading on Wednesday. The company's common stock will continue to trade in Europe on the Stockholm Stock Exchange under the symbol MAXM.

¿ Symyx Technologies Inc., of Santa Clara, Calif., said it will collaborate with Aventis Research & Technologies GmbH & Co. KG, of Frankfurt, Germany, to develop novel instrumentation for high-throughput analysis of pharmaceutical compounds. This instrumentation initially will be applied to develop catalysts and processes used in the synthesis of small-molecule drugs. Aventis and Symyx will share the costs under terms of the one-year agreement.

¿ Trimedyne Inc., of Irvine, Calif., said its 90 percent-owned subsidiary, Cardiodyne Inc., has begun testing its proprietary angiogenic composition, a "cocktail" of growth factors and other agents, to stimulate the growth of new blood vessels in the hearts of pigs. The purpose of the study, conducted at the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, is to determine if injections of Cardiodyne's angiogenic composition are able to restore blood flow and regional function to hearts in which a major coronary artery has been gradually occluded.